MA49236B1 - Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant - Google Patents
Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisantInfo
- Publication number
- MA49236B1 MA49236B1 MA49236A MA49236A MA49236B1 MA 49236 B1 MA49236 B1 MA 49236B1 MA 49236 A MA49236 A MA 49236A MA 49236 A MA49236 A MA 49236A MA 49236 B1 MA49236 B1 MA 49236B1
- Authority
- MA
- Morocco
- Prior art keywords
- antigen
- tumor associated
- novel
- relates
- antigen recognition
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
Abstract
La présente invention concerne des constructions de reconnaissance d'antigène contre des antigènes associés à une tumeur (magea1). L'invention concerne en particulier de nouvelles molécules à base de récepteur des lymphocytes t (tcr) qui sont sélectives et spécifiques à l'antigène exprimé par la tumeur. Le tcr de l'invention et les fragments de liaison à l'antigène associé à une tumeur dérivés de celui-ci sont utiles pour le diagnostic, le traitement et la prévention de maladies cancéreuses exprimant l'antigène associé à une tumeur. L'invention concerne en outre des acides nucléiques codant pour les constructions de reconnaissance d'antigène de l'invention, des vecteurs comprenant ces acides nucléiques, des cellules recombinantes exprimant les constructions de reconnaissance d'antigène et des compositions pharmaceutiques comprenant les composés de l'invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016123847.3A DE102016123847B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
PCT/EP2017/081800 WO2018104438A1 (fr) | 2016-12-08 | 2017-12-07 | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49236A MA49236A (fr) | 2020-04-15 |
MA49236B1 true MA49236B1 (fr) | 2022-02-28 |
Family
ID=61623755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49236A MA49236B1 (fr) | 2016-12-08 | 2017-12-07 | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant |
Country Status (14)
Country | Link |
---|---|
US (1) | US10874731B2 (fr) |
EP (1) | EP3551221B1 (fr) |
KR (1) | KR20190088539A (fr) |
CN (1) | CN110114085A (fr) |
AU (2) | AU2017373740C1 (fr) |
BR (1) | BR112019010972A2 (fr) |
CA (1) | CA3045233C (fr) |
CR (1) | CR20190278A (fr) |
DE (1) | DE102016123847B3 (fr) |
MA (1) | MA49236B1 (fr) |
MX (1) | MX2019006724A (fr) |
PE (1) | PE20191648A1 (fr) |
TW (1) | TWI736719B (fr) |
WO (1) | WO2018104438A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102375218B1 (ko) * | 2016-12-08 | 2022-03-17 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
EP3595708A4 (fr) * | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | Tcr spécifiques de mage-a1 à haute affinité et leurs utilisations |
EP3670530A1 (fr) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Récepteurs de cellules t spécifiques de cd22 et thérapie par lymphocytes t adoptive pour le traitement des malignités des cellules b |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
EA202192726A1 (ru) | 2019-04-04 | 2022-01-26 | Медиджин Иммьюнотерапиз Гмбх | Magea1-специфические т-клеточные рецепторы и их использование |
CR20210669A (es) | 2019-05-27 | 2022-05-05 | Immatics Us Inc | Vectores víricos y uso de los mismos en terapias celulares adoptivas |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
JP2022554349A (ja) * | 2019-11-05 | 2022-12-28 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Hla拘束性hormad1 t細胞受容体およびその使用 |
CN111208304B (zh) * | 2020-01-20 | 2023-06-16 | 中国医学科学院北京协和医院 | 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途 |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
TW202227616A (zh) * | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Cd8多肽、組合物及其使用方法 |
WO2022233957A1 (fr) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Polypeptides de liaison à l'antigène bma031 |
WO2023044488A1 (fr) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Déplétion monocytaire des populations de lymphocytes t pour une thérapie par lymphocytes t |
WO2023081925A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Traitement combiné de thérapie cellulaire adoptive et compositions associées |
WO2023081461A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Procédés de génération de sphéroïdes cellulaires |
US20230310607A1 (en) | 2021-11-09 | 2023-10-05 | T-Knife Gmbh | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
WO2023133296A2 (fr) * | 2022-01-07 | 2023-07-13 | Sorrento Therapeutics, Inc. | Récepteurs de lymphocytes t gamma delta ciblant pd-l1 modifiés |
WO2023175069A1 (fr) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Bibliothèque d'appariement de régions constantes de tcr pour tcr pramevld |
WO2023175070A1 (fr) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Bibliothèque d'appariement de régions constantes de tcr |
WO2023179795A1 (fr) * | 2022-03-25 | 2023-09-28 | 立凌生物制药(苏州)有限公司 | Procédé d'obtention rapide, simple et pratique de tcr correctement appariés, et tcr obtenus |
WO2023212655A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
WO2023212691A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation |
WO2023212697A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
CN116970066B (zh) * | 2023-09-19 | 2024-03-12 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (fr) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Souris transgéniques capables de produire des anticorps hétérologues |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
EP1257289A1 (fr) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie |
US20140378389A1 (en) * | 2011-09-15 | 2014-12-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
PT2951202T (pt) * | 2013-01-29 | 2020-07-07 | Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch | Moléculas de ligação de alta avidez que reconhecem mage-a1 |
MX2015016963A (es) * | 2013-06-10 | 2016-08-08 | Dana Farber Cancer Inst Inc | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. |
US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
CN105316362B (zh) * | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换系统及其方法 |
GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
CN106749620B (zh) | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
JP6989138B2 (ja) | 2016-06-17 | 2022-01-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | T細胞受容体及びその使用 |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
KR102375218B1 (ko) * | 2016-12-08 | 2022-03-17 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
EP3595708A4 (fr) | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | Tcr spécifiques de mage-a1 à haute affinité et leurs utilisations |
KR20200065026A (ko) | 2017-09-29 | 2020-06-08 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 |
-
2016
- 2016-12-08 DE DE102016123847.3A patent/DE102016123847B3/de active Active
-
2017
- 2017-12-07 PE PE2019001076A patent/PE20191648A1/es unknown
- 2017-12-07 EP EP17829609.1A patent/EP3551221B1/fr active Active
- 2017-12-07 AU AU2017373740A patent/AU2017373740C1/en active Active
- 2017-12-07 BR BR112019010972A patent/BR112019010972A2/pt unknown
- 2017-12-07 MX MX2019006724A patent/MX2019006724A/es unknown
- 2017-12-07 CR CR20190278A patent/CR20190278A/es unknown
- 2017-12-07 CA CA3045233A patent/CA3045233C/fr active Active
- 2017-12-07 MA MA49236A patent/MA49236B1/fr unknown
- 2017-12-07 CN CN201780075284.2A patent/CN110114085A/zh active Pending
- 2017-12-07 US US15/834,633 patent/US10874731B2/en active Active
- 2017-12-07 WO PCT/EP2017/081800 patent/WO2018104438A1/fr unknown
- 2017-12-07 KR KR1020197019005A patent/KR20190088539A/ko not_active IP Right Cessation
- 2017-12-08 TW TW106143114A patent/TWI736719B/zh active
-
2021
- 2021-05-14 AU AU2021203099A patent/AU2021203099A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180161396A1 (en) | 2018-06-14 |
DE102016123847B3 (de) | 2018-04-05 |
PE20191648A1 (es) | 2019-11-07 |
WO2018104438A1 (fr) | 2018-06-14 |
KR20190088539A (ko) | 2019-07-26 |
CN110114085A (zh) | 2019-08-09 |
EP3551221B1 (fr) | 2021-11-10 |
EP3551221A1 (fr) | 2019-10-16 |
AU2017373740B2 (en) | 2021-03-18 |
MA49236A (fr) | 2020-04-15 |
BR112019010972A2 (pt) | 2019-10-15 |
MX2019006724A (es) | 2019-08-22 |
AU2017373740C1 (en) | 2021-08-26 |
TWI736719B (zh) | 2021-08-21 |
TW201827458A (zh) | 2018-08-01 |
CR20190278A (es) | 2019-11-19 |
CA3045233C (fr) | 2023-11-28 |
AU2021203099A1 (en) | 2021-06-10 |
US10874731B2 (en) | 2020-12-29 |
AU2017373740A1 (en) | 2019-06-27 |
CA3045233A1 (fr) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49236B1 (fr) | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant | |
MA45976B1 (fr) | Récepteurs de lymphocytes t et thérapie immunitaire les utilisant | |
CO2019006914A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
WO2018172533A3 (fr) | Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame | |
MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA43328A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
MA42045B1 (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
WO2019002444A9 (fr) | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant | |
EA201891638A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
MA41237B1 (fr) | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers | |
MA47367B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
EA202192252A1 (ru) | Высокоавидные т-клеточные рецепторы к wt1 и их применения | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
EA202090712A1 (ru) | Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием | |
EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением | |
EA202190186A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака | |
CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
EA201991151A1 (ru) | Новые т-клеточные рецепторы и иммунотерапия с их применением | |
CY1124826T1 (el) | Υποδοχεις τ-κυτταρων και ανοσοθεραπεια με τη χρηση των ιδιων |